NNMT(Sprint Bioscience)

Non-alcoholic fatty liver disease (NAFLD), characterized by abnormal lipid accumulation in hepatocytes, is a prevalent metabolic disorder strongly linked to insulin resistance and obesity. Emerging evidence highlights the central role of nicotinamide N-methyltransferase (NNMT) in NAFLD pathogenesis through its regulation of nicotinamide adenine dinucleotide (NAD⁺) metabolism, the methionine cycle, epigenetic modifications, and gut microbiota. NNMT methylates NAM to methylnicotinamide (MNAM), consuming SAM, raising SAH/Hcy, depleting NAD⁺ and worsening oxidative stress. Studies in animal models have demonstrated that NNMT knockout ameliorates hepatic steatosis, inflammation, and fibrosis, while NNMT overexpression aggravates metabolic dysregulation. Furthermore, NNMT modulates the activity of NAD⁺-dependent enzymes such as SIRT1 and PARPs, impacting mitochondrial function, insulin signaling, and epigenetic reprogramming. Notably, NNMT interacts with the gut microbiota to perturb bile acid metabolism and intestinal barrier integrity, thereby exacerbating hepatic lipid accumulation via the gut-liver axis. Although NNMT-targeted oligonucleotide therapies and small-molecule inhibitors exhibit anti-steatotic and anti-fibrotic potential in preclinical models, clinical translation remains hindered by translational gaps such as limited selectivity and poor in vivo stability. This review systematically examines the multidimensional regulatory network of NNMT in NAFLD and evaluates its therapeutic prospects, providing a foundation for developing precision interventions targeting NNMT.